Boston Scientific (NYSE:BSX) EVP Joseph Michael Fitzgerald Sells 50,000 Shares

Key Points

• Joseph Michael Fitzgerald, Executive Vice President of Boston Scientific, sold 50,000 shares of stock for a total of $5,271,500, marking a 21.90% decrease in his ownership.
• Boston Scientific's stock was up 0.7%, reaching $107.38, with a market capitalization of $159.10 billion and a P/E ratio of 63.91.
• The company reported $0.75 EPS in its latest earnings, exceeding estimates, and anticipates Q3 2025 EPS guidance between 0.700 and 0.720.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) EVP Joseph Michael Fitzgerald sold 50,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total value of $5,271,500.00. Following the sale, the executive vice president directly owned 178,342 shares of the company's stock, valued at approximately $18,802,597.06. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Joseph Michael Fitzgerald also recently made the following trade(s):

• On Friday, August 1st, Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00.
• On Tuesday, July 1st, Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock. The shares were sold at an average price of $106.97, for a total value of $5,348,500.00.

Boston Scientific Trading Down 0.1%

Shares of NYSE:BSX traded down $0.15 during trading on Friday, reaching $107.14. 4,062,436 shares of the stock were exchanged, compared to its average volume of 5,736,611. The firm's 50-day moving average price is $104.77 and its 200 day moving average price is $102.15. The firm has a market cap of $158.76 billion, a price-to-earnings ratio of 63.78, a price-to-earnings-growth ratio of 2.58 and a beta of 0.65. Boston Scientific Corporation has a 12-month low of $80.64 and a 12-month high of $108.94. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. During the same period in the previous year, the company posted $0.62 earnings per share. Boston Scientific's revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Boston Scientific

Several large investors have recently added to or reduced their stakes in BSX. HM Payson & Co. raised its holdings in shares of Boston Scientific by 1.4% during the first quarter. HM Payson & Co. now owns 6,875 shares of the medical equipment provider's stock worth $694,000 after purchasing an additional 98 shares during the period. Riverwater Partners LLC grew its position in shares of Boston Scientific by 3.3% during the 2nd quarter. Riverwater Partners LLC now owns 3,104 shares of the medical equipment provider's stock valued at $333,000 after buying an additional 98 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management raised its stake in Boston Scientific by 3.8% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 2,711 shares of the medical equipment provider's stock worth $291,000 after acquiring an additional 99 shares during the period. IVC Wealth Advisors LLC raised its stake in Boston Scientific by 4.9% during the second quarter. IVC Wealth Advisors LLC now owns 2,199 shares of the medical equipment provider's stock worth $236,000 after acquiring an additional 102 shares during the period. Finally, Park Square Financial Group LLC lifted its holdings in shares of Boston Scientific by 5.2% in the 1st quarter. Park Square Financial Group LLC now owns 2,066 shares of the medical equipment provider's stock worth $208,000 after purchasing an additional 103 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Morgan Stanley increased their price target on Boston Scientific from $120.00 to $125.00 and gave the company an "overweight" rating in a report on Friday, May 16th. Oppenheimer raised their target price on Boston Scientific from $110.00 to $118.00 and gave the company a "market perform" rating in a report on Thursday, July 24th. Robert W. Baird boosted their price target on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. UBS Group upped their price target on Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a report on Thursday, July 24th. Finally, Leerink Partners assumed coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $117.50.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.